Journal ArticleDOI
4. Modelling Survival Data in Medical Research
About:
This article is published in Journal of The Royal Statistical Society Series A-statistics in Society.The article was published on 1995-01-01. It has received 1092 citations till now. The article focuses on the topics: Medical research.read more
Citations
More filters
Posted Content
Cross validating extensions of kernel, sparse or regular partial least squares regression models to censored data
TL;DR: A vast simulation study was carried out to evaluate more than a dozen of potential cross-validation criteria and found a new robust measure based on the Schmid score and the R coefficient of determination for least absolute deviation: the integrated R Schmid Score weighted.
Investigating the determinants of timing of first childbirth among women of the reproductive age In Mozambique
TL;DR: The results showed that variables like smoking, working and knowledge of contraceptive use among women of the reproductive age had a positive effect on the response while age at first sexual intercourse had a negative effect on pregnancy outcome.
Asymptotic Efficiencies of the Survival Functions Estimators for the Exponential Distribution
TL;DR: In this article, an estimator of the survival time, Xi, for the i th patient on a clinical trial with censoring time, Ti (dropping out of the trial) and its properties, when both survival and censoring times are exponentially distributed, considered.
Dissertation
Survival Analysis of Breast Cancer Patients in Ghana: Using the Non Parametric and Parametric Approaches.
TL;DR: It is suggested that proportionality assumption should be assessed and other less popular PH models should be considered to provide the best fitted models and hence a better prediction.
Inference on survival data under nonproportional hazards
TL;DR: In this paper, a weighted log-rank test with non-proportional hazards is proposed to detect a difference between two survival distributions when populations become homogeneous as time progresses and the results indicate that the extended test performs with a higher sensitivity than the existing nonparametric method.
References
More filters
Journal ArticleDOI
Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis
Geoffrey A. Block,Preston S. Klassen,J. Michael Lazarus,Norma J. Ofsthun,Edmund G. Lowrie,Glenn M. Chertow +5 more
TL;DR: Hyperphosphatemia and hyperparathyroidism were significantly associated with all-cause, cardiovascular, and fracture-related hospitalization, and the population attributable risk percentage for disorders of mineral metabolism was 17.5%, owing largely to the high prevalence of hyperph phosphatemia.
Journal ArticleDOI
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer,Thomas E. Hutson,Piotr Tomczak,M. Dror Michaelson,Ronald M. Bukowski,Stéphane Oudard,Sylvie Negrier,Cezary Szczylik,Roberto Pili,Georg A. Bjarnason,Xavier Garcia-del-Muro,Jeffrey A. Sosman,Ewa Solska,George Wilding,John A. Thompson,Sindy T. Kim,Isan Chen,Xin Huang,Robert A. Figlin +18 more
TL;DR: Sunitinib demonstrates longer overall survival compared with IFN-alpha plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC, highlighting an improved prognosis in patients with RCC in the era of targeted therapy.
Journal ArticleDOI
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote,Claes G. Tropé,Frédéric Amant,G.B. Kristensen,Tom Ehlen,N Johnson,René H.M. Verheijen,Maria E. L. van der Burg,A. J. Lacave,Pierluigi Benedetti Panici,Gemma G. Kenter,Antonio Casado,Cesar Mendiola,Corneel Coens,Leen Verleye,Gavin Stuart,Sergio Pecorelli,Nicholas Reed +17 more
TL;DR: Neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary debulked surgery followed by chemotherapy as a treatment option for patients with bulky stage IIIC or IV ovarian carcinoma in this study.
Journal ArticleDOI
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
TL;DR: Five prognostic factors for predicting survival were identified and used to categorize patients with metastatic RCC into three risk groups, for which the median survival times were separated by 6 months or more.